JP2018186815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018186815A5 JP2018186815A5 JP2018111489A JP2018111489A JP2018186815A5 JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5 JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018111489 A JP2018111489 A JP 2018111489A JP 2018186815 A5 JP2018186815 A5 JP 2018186815A5
- Authority
- JP
- Japan
- Prior art keywords
- vlp
- virus
- protein
- polynucleotide
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 241000710929 Alphavirus Species 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 6
- 102100021696 Syncytin-1 Human genes 0.000 claims 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 101710091045 Envelope protein Proteins 0.000 claims 4
- 101710188315 Protein X Proteins 0.000 claims 4
- 241000714474 Rous sarcoma virus Species 0.000 claims 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 101710172711 Structural protein Proteins 0.000 claims 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 101710177291 Gag polyprotein Proteins 0.000 claims 2
- 108010093013 HLA-DR1 Antigen Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 241000710960 Sindbis virus Species 0.000 claims 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 1
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 101710145006 Lysis protein Proteins 0.000 claims 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 claims 1
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims 1
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 1
- 101710144128 Non-structural protein 2 Proteins 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims 1
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 102100031056 Serine protease 57 Human genes 0.000 claims 1
- 101710197596 Serine protease 57 Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 claims 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003197 gene knockdown Methods 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 101150088264 pol gene Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 208000005925 vesicular stomatitis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615687P | 2012-03-26 | 2012-03-26 | |
| US61/615,687 | 2012-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Division JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018186815A JP2018186815A (ja) | 2018-11-29 |
| JP2018186815A5 true JP2018186815A5 (cg-RX-API-DMAC7.html) | 2019-01-17 |
| JP6585237B2 JP6585237B2 (ja) | 2019-10-02 |
Family
ID=47998556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Pending JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
| JP2018111489A Active JP6585237B2 (ja) | 2012-03-26 | 2018-06-12 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503322A Pending JP2015527296A (ja) | 2012-03-26 | 2013-03-15 | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9506041B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3663395B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2015527296A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013240248B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013148302A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010040023A2 (en) | 2008-10-03 | 2010-04-08 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for protein delivery |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| AU2013240248B2 (en) | 2012-03-26 | 2018-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| KR102467982B1 (ko) | 2013-12-16 | 2022-11-16 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법 |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| FR3036118B1 (fr) * | 2015-05-15 | 2019-07-12 | Flash Therapeutics | Particule retrovirale comportant au moins deux arn non viraux encapsides. |
| WO2016185125A1 (fr) * | 2015-05-15 | 2016-11-24 | Vectalys | Particule rétrovirale comportant au moins deux arn non viraux encapsidés |
| EP3310368B1 (en) | 2015-06-19 | 2025-07-16 | LGC Clinical Diagnostics, Inc. | Sindbis control virus |
| JP2018530314A (ja) | 2015-08-28 | 2018-10-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ウイルス様粒子からの感染性インフルエンザウイルスの生成 |
| US11135283B2 (en) | 2015-11-09 | 2021-10-05 | Immune Design Corp. | Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
| BR112019013862A2 (pt) | 2017-01-07 | 2020-04-14 | Selecta Biosciences Inc | dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos |
| AU2018241252B2 (en) | 2017-03-30 | 2024-09-19 | The University Of Queensland | Chimeric molecules and uses thereof |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| KR20200086670A (ko) | 2017-10-13 | 2020-07-17 | 셀렉타 바이오사이언시즈, 인크. | 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물 |
| JP2021500891A (ja) | 2017-10-25 | 2021-01-14 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス |
| MY207644A (en) | 2017-12-19 | 2025-03-07 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| JP7306721B2 (ja) * | 2018-07-13 | 2023-07-11 | 国立大学法人京都大学 | ウイルス様粒子及びその使用 |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| KR20220004121A (ko) | 2019-04-28 | 2022-01-11 | 셀렉타 바이오사이언시즈, 인크. | 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법 |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| CA3143327A1 (en) | 2019-06-13 | 2020-12-17 | J. Keith Joung | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| WO2021021674A1 (en) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| US11739303B2 (en) | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US20230212606A1 (en) | 2020-05-13 | 2023-07-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| TW202208405A (zh) | 2020-05-13 | 2022-03-01 | 美商阿科奧斯公司 | 用於治療ｓｌｃ２６ａ４相關聽力損失之組合物及方法 |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| MX2023006451A (es) | 2020-12-01 | 2023-06-15 | Akouos Inc | Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular. |
| KR20230127263A (ko) | 2020-12-29 | 2023-08-31 | 아카우오스, 인크. | Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법 |
| WO2022261343A1 (en) | 2021-06-09 | 2022-12-15 | Chimeron Bio Corporation | Peptide vlp-based vaccines |
| WO2022261355A1 (en) | 2021-06-09 | 2022-12-15 | Chimeron Bio Corporation | Self-amplifying rna-based vlp vaccines |
| MX2024003778A (es) | 2021-09-30 | 2024-04-10 | Akouos Inc | Composiciones y metodos para el tratamiento de la perdida de audicion asociada a kcnq4. |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| TW202408545A (zh) | 2022-07-08 | 2024-03-01 | 美國貝勒醫學院 | 整合的壓力反應抑制劑及其使用方法 |
| WO2024229309A2 (en) | 2023-05-03 | 2024-11-07 | Manifold Biotechnologies, Inc. | Methodsand compositions for high-throughput protein delivery, screening, and detection |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1004083A (en) | 1911-01-09 | 1911-09-26 | Henry Ritter | Method of making sash-bars and die for forming same. |
| US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| JPH06503821A (ja) | 1990-12-20 | 1994-04-28 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | Ｂ型肝炎表面抗原に基づくワクチン |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
| US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| US6555342B1 (en) | 1998-06-03 | 2003-04-29 | Uab Research Foundation | Fusion protein delivery system and uses thereof |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| US20020052040A1 (en) | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| JP4790984B2 (ja) | 2001-09-06 | 2011-10-12 | アルファヴァックス，インコーポレイテッド | アルファウイルスレプリコンベクター系 |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| US20080115199A1 (en) * | 2001-12-06 | 2008-05-15 | Albert Young | Scheme for device and user authentication with key distribution in a wireless network |
| US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| FR2862982B1 (fr) * | 2003-12-02 | 2006-04-28 | Genethon | Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale. |
| WO2005115444A2 (en) | 2004-04-14 | 2005-12-08 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| GB0426641D0 (en) | 2004-12-03 | 2005-01-05 | Bioactive Protein Delivery The | Protein delivery system |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| DE202006010918U1 (de) * | 2006-07-14 | 2006-10-05 | Flexi-Bogdahn Technik Gmbh & Co. Kg | Leineneinrichtung für eine mechanisch auf- und abrollbare Leine zum Führen von Tieren |
| WO2008115199A2 (en) | 2006-08-18 | 2008-09-25 | The University Of North Carolina At Chapel Hill | Chimeric virus vaccines |
| US20110250675A1 (en) * | 2008-03-26 | 2011-10-13 | Life Technologies Corporaiton | Virus-Like Particle Mediated Cellular Delivery |
| WO2010040023A2 (en) | 2008-10-03 | 2010-04-08 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods and compositions for protein delivery |
| CN102753582A (zh) * | 2009-11-03 | 2012-10-24 | 莱戈赛特医药股份有限公司 | 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP |
| AU2013240248B2 (en) | 2012-03-26 | 2018-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| KR102467982B1 (ko) | 2013-12-16 | 2022-11-16 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법 |
-
2013
- 2013-03-15 AU AU2013240248A patent/AU2013240248B2/en active Active
- 2013-03-15 EP EP19207297.3A patent/EP3663395B1/en active Active
- 2013-03-15 EP EP13712661.1A patent/EP2831225A1/en not_active Withdrawn
- 2013-03-15 US US14/388,441 patent/US9506041B2/en active Active
- 2013-03-15 JP JP2015503322A patent/JP2015527296A/ja active Pending
- 2013-03-15 WO PCT/US2013/031876 patent/WO2013148302A1/en not_active Ceased
-
2016
- 2016-06-23 US US15/190,992 patent/US10538743B2/en active Active
-
2018
- 2018-06-12 JP JP2018111489A patent/JP6585237B2/ja active Active
-
2019
- 2019-03-19 AU AU2019201911A patent/AU2019201911A1/en not_active Abandoned
- 2019-12-10 US US16/709,147 patent/US20200102545A1/en not_active Abandoned
-
2021
- 2021-10-01 AU AU2021240286A patent/AU2021240286B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018186815A5 (cg-RX-API-DMAC7.html) | ||
| JP6585237B2 (ja) | 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達 | |
| JP2015527296A5 (cg-RX-API-DMAC7.html) | ||
| JP5572144B2 (ja) | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 | |
| US8961995B2 (en) | Methods and compositions for alphavirus replicons | |
| US8709441B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| CA2410948C (en) | Method for the purification of alphavirus replicon particles | |
| JP2015522581A5 (cg-RX-API-DMAC7.html) | ||
| Tubulekas et al. | Alphavirus expression vectors and their use as recombinant vaccines: a minireview | |
| US6943015B2 (en) | Large scale production of packaged alphavirus replicons | |
| JP2010530245A5 (cg-RX-API-DMAC7.html) | ||
| JP2017515509A (ja) | ワクチン用途のための高力価ウイルス様ベシクルの進化の方法 | |
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| JP2024512808A (ja) | Ｃａｌｒ及びｊａｋ２ｔ細胞受容体 | |
| Lundstrom | Alphaviruses as expression vectors | |
| Lundstrom | The potential of self-amplifying RNA vaccines for infectious diseases and COVID-19 | |
| US20080118956A1 (en) | Viral Particles Containing An Alphavirus-Derived Vector And Method For Preparing Said Viral Particle | |
| US20050221493A1 (en) | Recombinant virus production for the manufacturing of vaccines | |
| Dorange et al. | Vesicular stomatitis virus glycoprotein: a transducing coat for SFV‐based RNA vectors | |
| Aranda et al. | Recent patents on alphavirus protein expression and vector production | |
| Zhu et al. | Selection and characterization of packaging cell lines for XJ-160 virus | |
| EP1590450A2 (en) | Recombinant virus production for the manufacturing of vaccines | |
| Polo et al. | Sindbis virus-based vectors for the study of class I antigen presentation in vitro and in vivo | |
| Lundstrom | RNA Viruses and Gene Therapy | |
| Yang et al. | Construction of nervous necrosis virus (NNV) genome-based DNA replicon vectors for the delivery of foreign antigens |